SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SANTA CRUZ BIOTECHNOLOGY, INC.

# NF2 (h3): 293T Lysate: sc-172383

## BACKGROUND

Neurofibromatosis type 2 (NF2) is a dominantly inherited disorder characterized by the occurance of bilateral vestibular schwannomas and other central nervous system tumors, including multiple meningiomas. NF2 occurs in about one of 40,000 live births. The NF2 gene is highly penetrant; NF2-affected individuals have a 95% chance of developing bilateral vestibular schwannomas. NF2 is distinct from NF1, which is characterized by an incidence of one in 4,000, maps to chromosome 17 and encodes a protein designated Neurofibromin, which is a large protein with a GAP domain. Genetic linkage studies of both sporadic and familial tumors suggest that NF2 is caused by inactivation of a tumor suppressor gene that maps on chromosome 22q12.2 and encodes a 595 amino acid protein whose function appears to be mediated by interaction with the cytoskeleton.

## REFERENCES


1. Rouleau, G.A., et al. 1990. Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22. Am. J. Hum. Genet. 46: 323-328.
2. Narod, S.A., et al. 1992. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Am. J. Hum. Genet. 51: 486-496.
3. Evans, D.G.R., et al. 1992. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J. Med. Genet. 29: 841-846.
4. DeClue, J.E., et al. 1992. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69: 265-273.
5. Trofatter, J.A., et al. 1993. A novel Moesin-, Ezrin-, Radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72: 791-800.


## CHROMOSOMAL LOCATION

Genetic locus: NF2 (human) mapping to 22q12.2.

## PRODUCT

NF2 (h3): 293T Lysate represents a lysate of human NF2 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

## STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

## APPLICATIONS

NF2 (h3): 293T Lysate is suitable as a Western Blotting positive control for human reactive NF2 antibodies.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

NF2 (E-2): sc-55574 is recommended as a positive control antibody for Western Blot analysis of enhanced human NF2 expression in NF2 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

## RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

## DATA




NF2 (E-2): sc-55574. Western blot analysis of NF2 expression in non-transfected: sc-117752 (**A**) and human NF2 transfected: sc-172383 (**B**) 293T whole cell lysates.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.